Prevalence and Its Clinical Correlation of JAK2V617F Mutation in Philadelphia chromosome negative myeloproliferative neoplasms in Vachira Phuket Hospital , Thailand
Keywords:
JAK2 V617F mutation, Essential thrombocythemia, Polycythemia veraAbstract
Philadelphia –negative ( Ph-) myeloproliferative neoplasms ( MPN ) include polycythemia vera ( PV ), essential thrombocythemia ( ET ), and primary myelofibrosis ( PMF ). According to the 2008 WHO recommendation, JAK2V617F mutation is a major diagnostic criterion for these diseases. Prevalence of such mutation, however, has been reported differently in numbers based on a study population; never before in the patients lives in southern of Thailand
. This study aims to explore the prevalence of JAK2V617F mutation in Thai MPN patients and examine its correlation to clinical features.
Totally 40 patients were composed of 26 (65 %) PV, 14 (35%) ET and 0 (0 %) PMF patients. Prevalence of JAK2V617F mutation was found 65 % (26/40), 69.2% (18/ 26 ) in PV, 57.1 % (8/14) in ET. We found that no difference in gender and frequency of hemorrhage, constitutional symptoms, pruritus, splenomegaly, cytoreductive treatment requirement, between JAK2 V617F mutated and unmutated PV and ET patients. There were no statistically significant difference in Hemoglobin (Hb), Hematocrit (Hct), white blood cells and platelet counts between JAK2 V617F mutated and unmutated ET patients. In PV, white blood cells counts of the mutant was higer than the wild type ( p = 0.007), the other variables were not found different. In conclusion, JAK2 V617F dose exist in Thai MPN patients. Its prevalence is close to other populations. Comprehensive prospective studies are necessary for determining the relationship of the JAK2 V617F mutation with clinical and laboratory findings.
References
Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders Blood. 2005;106(8):2920-2921.
Tefferi A, Lasho TL, Gilliland G. JAK2 mutations in myeloproliferative disorders. N Engl J Med. 2005;353(13):1416-1417.
Campbell PJ, Green AR. The myeloproliferative disorders N Engl J Med. 2006;355(23):2452- 2466.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative
disorders. Lancet 2005 ;365(9464):1054 - 61.
Lieu CH, Wu HS, Hon YC, Tsai WH. Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Intern Med J. 2008;38(6):422-426.
Kim JT, Cho YG, Choi SI, Lee YJ. JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasm.
Korean J Lab med.2010;3( 6):567-574.
Wong GC, Kam GL, Koay ES. JAK2 Mutations in Asian Patients with Essential thrombocytothemia. Intern Med J. 2014;41(2):191-196.
Namo Suksom yos, Supantitra Chanprasert, Chuanchom Maunpasitporn, Ponlapat Rojnuckarin. Prevalence of JAK2V617F Mutation and Its Clinical Correlation in Thais with Myeloproliferative Neoplasm. Int J Biol Med Res. 2012; 3(2):1801-1805.
Robert Kralovics, Francesco Passamonti, Andreas S. Buser, Soon-Siong Teo. A Gain-of- Function Mutation of JAK2 in Myeloproliferative Disorders. N Engl J Med 2005;352 :1779-90.
Marta R, Goette N, Lev P, Heller P, Kornblihtt L, Vassallu P, et al. Increased levels of plasma interleukin-6 soluble receptor in patients with essential thrombocythemia. Haematologica. 2004;89(6):657-663.
Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic
myeloproliferative diseases. Br J Haematol. 2005;130(5):709-715.
Goette NP, Lev PR, Heller PG, Kornblihtt LI. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in
myeloproliferative neoplasms. Cytokine. 2010; 51(1):67-72.
ปัญญา เสกสรรค์, วีระศักดิ์ นาวารวงศ์, ต้นตนัย นำเบญจพล. แนวทางการรักษาโรคโลหิตวิทยาในประเทศไทย 2558.
